Skip to main content
ALMR
NASDAQ Industrial Applications And Services

Alamar Biosciences Delivers 82% Revenue Growth in Q2, Guides for 59% Full-Year Expansion

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$27.99
Mkt Cap
$1.94B
52W Low
$18.845
52W High
$29.43
52W Position info
49% above low
Off High info
4.9% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

ALMR sits 49% above its 52-week low of $18.845.

Summary

Alamar Biosciences posted Q2 revenue of $29.4M (+82% YoY) and guided for full-year 2026 revenue of $116M–$120M, representing 59% growth at the midpoint. Consumable revenue nearly tripled, and gross margin improved to 60%.


Key Events · Earnings and Guidance · ALMR

  • Q2 Revenue Surges 82%

    Driven by a 147% jump in consumable revenue to $15.5 million, total revenue reached $29.4 million, up from $16.2 million in Q2 2025.

  • Full-Year 2026 Guidance Initiated

    Management expects full-year revenue of $116–$120 million, representing 59% growth at the midpoint compared to 2025.

  • Gross Margin Expands to 60%

    Reflecting manufacturing efficiencies and a favorable shift toward high-margin consumables, gross margin improved from 53% a year ago.

  • Strong Cash Position

    Cash, equivalents, and short-term investments totaled $256.3 million as of June 30, 2026, providing substantial runway for growth investments.


Analysis · ALMR · Industrial Applications And Services

A standout second quarter saw revenue climb 82% to $29.4 million, fueled by a 147% surge in consumable sales. Gross margins expanded to 60%, and the company introduced full-year 2026 revenue guidance of $116–$120 million, implying 59% growth at the midpoint. While operating losses widened on planned investments, the $256.3 million cash position provides ample runway. Together, the results and outlook underscore the commercial momentum of the NULISA platform and the recent launch of high-value panels like eMTBR-tau and Immune 340.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 35.2% of the 2649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ALMR was trading at $27.99 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $18.85 to $29.43. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ALMR - Latest Insights

ALMR
Nov 03, 2026, 9:00 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $30.00
Real-time Price: $26.91 info
Change: -$3.09 (-10%) info
Market Cap: $1.867B info
ALMR
Nov 03, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $31.50
Real-time Price: $26.91 info
Change: -$4.59 (-15%) info
Market Cap: $1.867B info
ALMR
Nov 03, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $31.50
Real-time Price: $26.91 info
Change: -$4.59 (-15%) info
Market Cap: $1.867B info
ALMR
Oct 14, 2026, 8:20 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $25.37
Real-time Price: $26.91 info
Change: +$1.54 (+6%) info
Market Cap: $1.867B info
ALMR
Aug 11, 2026, 1:25 PM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $36.44
Real-time Price: $26.91 info
Change: -$9.53 (-26%) info
Market Cap: $1.867B info